The role of plasminogen activator receptor-in cancer invasion and dormancy

Medicina

Volumn 59, Issue 5 II, 1999, Pages 547-552

  Ossowski, Liliana ^a,b   Ghiso, Julio Aguirre ^a   Liu, David ^a   Yu, Wen ^a   Kovalski, Katherine ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Box 1178 ^*  (United States)

Author keywords

5b1 integrin; Cancer dormancy; ERK; Intravasation; Invasion; uPA receptor (uPAR); Urokinase plasminogen activator (uPA)

Indexed keywords

CELL SURFACE RECEPTOR; PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL; ARTICLE; CANCER INVASION; CHICK EMBRYO; HUMAN; METABOLISM; METASTASIS; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TIME;

ANIMALS; CHICK EMBRYO; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PLASMINOGEN ACTIVATORS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TIME FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033250756     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. Aguirre Ghiso J., Kovalski K, Ossowski L. (1999) Tumor dormancy induced by down regulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. The journal of Cell Biology 147: 89-103.
2. Anchini E, Fibbi G, Pucci M, Caldini R, Chevanne M, Del Rosso M. (1994) Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts transfected with human urokinase receptor. Exp. Cell Res. 213: 438-48.
3. Axelrod JH, Reich R, Miskin R (1989) Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells. Mol. Cell. Biol 9: 2133-41.
4. Bianchi E, Cohen RL, Thor AT, Todd RF 3rd, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS (1994) The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue Cancer Res. 54: 861-6.
5. Bugge T.H., Flick M.J., Daugherty C.C., and Degen J.A. (1995) Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes and Dev. 9: 794-807.
6. Blasi F. (1993) Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays. 1993 15): 105-11. Review.
7. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L (1994) Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction. J. Cell Biol. 126: 259-70.
8. Cajot J-F., Schleuning W-D., Medcalf R.L., Bamat J., Testuz J., Libermann . and Sordat B. (1989) Mouse L-cells expressing human pro-urokinase type plasminogen activator: effect on extracellular matrix degradation and invasion. J. Cell Biol. 109: 915-25.
9. Carriero MV, Franco P, Del-Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M (1994) Tissue distribution of soluble and receptor bound urokinase in human breast cancer using a panel of monoclonal antibodies Cancer Res. 54: 5445-54.
10. Crowley CW, Cohen R, Lucas BK, Liu G, Shuman MA, Levinson AD (1993) Prevention of metastasis by inhibition of the urokinase receptor. PNAS 90: 5021-5.
11. Cubellis MV, Andreasen P, Ragno P, Mayer M, Dano K, Blasi F (1989) Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc.Natl.Acad.Sci USA 86: 4828-34.
12. Danø K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen L, Skriver L Plasminogen activators, tissue degradation and cancer. (1985) Adv. Cancer Res. 44: 139-266
13. DeBruin PA, Griffioen G, Verspaget HV, Verheijen JH (1987) Plasminogen activators and tumor development in the human colon. Activity levels in normal mucosa, adenomateous tissue, polyps and adenocarcinomas. Cancer Res. 47: 4654-7.
14. Del Rosso M, Anichini E, Pedersen N, Blasi F, Fibbi G, Pucci M, Ruggiero M (1993) Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells. Biochem. Biophys. Res. Commun. 190: 347-52.
15. de Vries TJ, Quax PH, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, van Muijen,GN (1994) Plasminogen activators, their inhibitors, and urokinase receptor emerge inlate stages of melanocytic tumor progression. Am J Pathol 144: 70-81.
16. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennely JJ (1990) Urokinase plasminogen activator and prognosis in breast cancer. Lancet 13: 108-11.
17. Dumler I, Petri T, Schleuning W-D (1993) Interaction of urokinase-type plasminogen activator (uPA) with its cellular receptor (uPAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett. 322: 37-40 .
18. Dumler I, Petri T, Schleuning W-D (1994) Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells. FEBS Lett. 343: 103-6.
19. Ellis V., Scully M.F. and Kakar V.V. (1989) Plasminogen activation initiated by single-chain urokinase type plasminogen activator. Potentiation by U937 monocytes. J. Biol. Chem. 264: 2184-8.
20. Ellis V., Behrendt N. and Danø K. (1991) Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J.Biol. Chem. 266: 12752-8.
21. Fibbi G, Ziehe M, Morbidelli, L., Magnelli, L., Del Rosso, M. (1988) Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp. Cell Res. 179: 385-95.
22. Folkman J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med., 1: 27-31.
23. Gladson C.L., Pijuan-ThompsonV., Olman M.A., Gillespie G.Y. and Yacoud I.Z. (1995) Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Pathol. 146: 1150-60.
24. Grøndahl-Hansen J, Ralfkiaer E, Kirkeby L, Kristensen P, Lund LR, Dano K (1991) Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans Am. J. Pathol. 138: 111-7.
25. Goodson RJ, Doyle MV, Kaufman SE, Rosenberg S (1994) High affinity urokinase receptor antagonists identified with bacteriophage peptide display. PNAS 91: 7129-33.
26. Gudewicz PW, Gilboa N (1987) Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem. Biophys. Res. Commun. 147: 1176-81.
27. Hearing VJ, Law LW, Corti A, Appella E, Blasi F (1988) Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res. 48: 1270-8.
28. Janicke F, Schmidt M, Hollrieder A, Babic R, Ulm K, Gossner W, Graeff H (1990) Urokinase-type plasminogen activator (uPA) is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78.
29. Kariko K, Megyeri K, Xiao Q, Barnathan ES (1994) Lipofectin aided cell delivery of ribozyme targeted to human urokinase receptor mRNA. FEBS-Lett. 352: 41-4.
30. Kim J, Yu W., Kovalski K., and Ossowski L. (1998) Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell. 1998 94: 353-62.
31. Konakova M., Hucho F. and Schleuning W.D. (1998) Downstream targets of urokinase- type plasminogen-activator-mediated signal transduction. Eur. J. Biochem. 253: 421-9.
32. Kook Y.H., Adamski J., Zelent A. and Ossowski L. (1994) The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 13: 3983-91.
33. Koshelnick Y, Ehart M, Hufnagl P, Heinrich PC, Binder BR. (1997). Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J Biol Chem 1997 272: 28563-7.
34. Kristensen P., Eriksen J., Blasi F. and Dano K. (1991) Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J. Cell Biol. 115: 1763-71.
35. Marches R., Scheuermann R.H. and Uhr J.W. (1998) Cancer dormancy: role of cyclin-dependent kinase inhibitors in induction of cell cycle arrest mediated via membrane IgM. Cancer Res. 58: 691-7.
36. Mazzieri R., Masiero L., Zanetta L., Monea S., Onisto M., Garbisa S., and Mignatti P. (1997) Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell bound reactants. EMBO J., 16: 2319-32.
37. Mignatti P, Robbins E, Rifkin DB (1986) Tumor invasion through the human amniotic membrane: Requirement for proteinase cascade Cell 47: 487-98.
38. Mignatti P, Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol. Reviews. 73: 161-95.
39. Mohanam S, Sawaya RE, Yamamoto M, Bruner JM, Nicholson GL, Rao JS (1994) Proteolysis and invasiveness of brain tumors: role of urokinase-type plasminogen activator receptor. Neurooncol 22: 153-60.
40. Nguyen D.H., Hussaini I.M. and Gonias S.L. (1998) Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility. J. Biol. Chem. 273: 8502-7.
41. Odekon LE, Sato Y, Rifkin DB (1992) Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J. Cell. Physiol. 150: 258-63.
42. Ossowski L, Reich E (1980) Experimental model for quantitative study of metastasis Cancer Res. 40: 2300-9 .
43. Ossowski L, Reich E (1983) Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611-9.
44. Ossowski L (1988a) Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell 52: 321-8.
45. Ossowski L (1988b) In vivo invasion of modified membrane by tumor cells: the role of cell surface-bound urokinase. J. Cell Biol. 107: 2437-45.
46. Ossowski L, Clunie G, Masucci T, Blasi F (1991) In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J. Cell Biol. 115: 1107-12.
47. Ploug M., Ronne E., Behrendt N., Jensen A.L., Blasi F. and Danq, K. (1991) Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processign nad membrane anchoring by glycosyl-phosphtidyl inositol. J.Biol. Chem. 266: 12524-34.
48. Ploug M., Ellis V., and Danø K. (1994) Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphtalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. FEBS Lett.349: 163-8.
49. Pyke C, Graem N, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Brunner N, Dano K (1993) Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma Cancer Res. 53: 1911-1915
50. Pyke C, Kristensen P, Ralkfiaer E, Ronne E, Grondahl-Hansen J, Eriksen J, Blasi F, Dano K (1991) Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells in invasive foci in human colon adenocarcinomas Am. J. Path. 138: 1059-67.
51. Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S, Del Rosso M (1995) Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res. 55: 90-5.
52. Quax PHA, Pedersen N, Masucci MT, Weeningverhoeff EJD, Dano K, Verheijnen JH, Blasi F (1991) Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul. 2: 793-803.
53. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. (1996) Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15: 1572-82.
54. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danø K, Appella E, Blasi F (1990) Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface plasmin-dependent proteolysis. EMBO J. 9: 467-74.
55. Schlechte W, Murano G, Boyd D (1989) Examination of the role of urokinase receptors in human colon cancer mediated laminin degradation. Cancer Res. 49: 6064-9.
56. Stahl A, Mueller BM (1994) Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro Cancer Res. 54: 3066-71.
57. Stephens, R.W., Pollanen,J., Tapiovara, H., et al., (1989) Activationof pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with with surfacebound reactants. J.Cell Biol. 1108: 1987-95.
58. Stoppelli MP, Corti A, Sofientini A, Cassani G, Blasi F, Assoian RK (1985) Differentiation-enhanced binding of the amino terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci USA 82: 4939-43.
59. Suzuki S., Hayashi Y., Wang T., Morita Y., Kawasaki K., Ohta K., Aoyama N., Kim S.R., Itoh H., Kuroda Y. and Doe W.F (1998) Urokinase type plasminogen activator receptor expression in colorectal carcinoma neoplasms. Gut 43: 798-805.
60. Tang H.; Kerins D.M., Hao Q., Inagami T. and Vaughan D.E. (1998) The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J. Biol. Chem. 273: 18268-72.
61. Testa JE, Quigley JP (1990) The role of plasminogen activator in aggressive tumor behavior. Cancer Metastasis Rev. 9: 353-67.
62. Toolan HW (1954) Transplantable human neoplasms maintained in cortisone-treated laboratory animals: HS#1, H.Ep.#1, H.Ep.#2, H.Ep.#3 and H.Emb.#1. Cancer Res. 14: 660-6.
63. Vassalli J-D, Baccino D, Belin (1985) A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100: 86-92.
64. Yu W, Kim J, Ossowski L (1997) Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 137: 767-77.